AZTA vs. FOLD, ARWR, IMCR, TXG, AMED, GDRX, PGNY, LTH, JANX, and IDYA
Should you be buying Azenta stock or one of its competitors? The main competitors of Azenta include Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Immunocore (IMCR), 10x Genomics (TXG), Amedisys (AMED), GoodRx (GDRX), Progyny (PGNY), Life Time Group (LTH), Janux Therapeutics (JANX), and IDEAYA Biosciences (IDYA). These companies are all part of the "medical" sector.
Amicus Therapeutics (NASDAQ:FOLD) and Azenta (NASDAQ:AZTA) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
Azenta has higher revenue and earnings than Amicus Therapeutics. Azenta is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amicus Therapeutics had 4 more articles in the media than Azenta. MarketBeat recorded 24 mentions for Amicus Therapeutics and 20 mentions for Azenta. Amicus Therapeutics' average media sentiment score of 0.54 beat Azenta's score of 0.35 indicating that Azenta is being referred to more favorably in the news media.
99.1% of Azenta shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 1.8% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Amicus Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Azenta has a net margin of -23.12% compared to Azenta's net margin of -34.73%. Amicus Therapeutics' return on equity of 0.81% beat Azenta's return on equity.
Amicus Therapeutics currently has a consensus target price of $18.40, suggesting a potential upside of 99.35%. Azenta has a consensus target price of $68.40, suggesting a potential upside of 32.56%. Given Azenta's stronger consensus rating and higher probable upside, equities research analysts clearly believe Amicus Therapeutics is more favorable than Azenta.
Amicus Therapeutics received 496 more outperform votes than Azenta when rated by MarketBeat users. Likewise, 73.47% of users gave Amicus Therapeutics an outperform vote while only 39.58% of users gave Azenta an outperform vote.
Summary
Amicus Therapeutics beats Azenta on 10 of the 18 factors compared between the two stocks.
Get Azenta News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
